EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSAOCG00000009908
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSAOCG00000017608
Gene Symbol: GUCY1A2
4 Cross references
204 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSAOCG00000009978
Gene Symbol: GUCY1B1
3 Cross references
211 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSAOCG00000019247
Gene Symbol: HSP90AB1
3 Cross references
333 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha

Ensembl ID : ENSAOCG00000023994
Gene Symbol: LOC111573807
3 Cross references
317 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha 1

Ensembl ID : ENSAOCG00000024001
Gene Symbol: LOC111573802
3 Cross references
305 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSAOCG00000008840
Gene Symbol: LOC111563689
3 Cross references
512 Possible Orthologues:

High Mobility Group-T Protein-Like

Ensembl ID : ENSAOCG00000000516
Gene Symbol: LOC111588264
2 Cross references
498 Possible Orthologues:

Histamine H2 Receptor-Like

Ensembl ID : ENSAOCG00000007558
Gene Symbol: LOC111575947
3 Cross references
192 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSAOCG00000012021
Gene Symbol: HRH1
4 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSAOCG00000004938
Gene Symbol: HRH2
3 Cross references
181 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSAOCG00000015346
Gene Symbol: HDAC10
3 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).